Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03236311 · ClinicalTrials.gov registry record · Phase 2
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
A Phase 2 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03236311 is a Phase 2 study that was terminated before completion, run by Sanofi. The registered enrollment target is 10 participants.
The verdict
NCT03236311, a Phase 2 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Primary Objective: To assess the effects of SAR407899 on coronary vasomotor function using the coronary flow reserve (CFR) in participants with microvascular angina (MVA) and/or persistent stable angina despite angiographically successful percutaneous coronary intervention (PCI). Secondary Objectives: * To assess the effects of SAR407899 on quality of life using Seattle Angina Questionnaire physical limitation scale (SAQ-PL) in participants with MVA and/or persistent stable angina despite angiographically successful PCI. * To assess the safety of SAR407899 in participants with MVA and/or persistent stable angina despite angiographically successful PCI with a focus on identified risks such as hypotension and orthostatic hypotension. * To assess SAR407899 plasma concentrations in MVA participants and/or persistent stable angina despite angiographically successful PCI.
Interventions
- DRUG Placebo
- DRUG Regadenoson
- DRUG Adenosine
- DRUG 13N-ammonia
- DRUG SAR407899
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-10-12 |
| Est. Completion | 2018-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03236311
The ClinicalTrials.gov registry entry for NCT03236311 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03236311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03236311 about?
NCT03236311 is a clinical study titled "A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI". Primary Objective: To assess the effects of SAR407899 on coronary vasomotor function using the coronary flow reserve (CFR) in participants with microvascular angina (MVA) and/or persistent stable angina despite angiographically successful percutaneous coronary intervention (PCI). Secondary Objecti...
What is the current status of trial NCT03236311?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-10-12. Estimated completion is 2018-07-23.
What interventions are being tested in trial NCT03236311?
The interventions under investigation include: Placebo (DRUG), Regadenoson (DRUG), Adenosine (DRUG), 13N-ammonia (DRUG), SAR407899 (DRUG).
Who is sponsoring clinical trial NCT03236311?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.